Use of a Lymphatic Drug Delivery System and Sonoporation to Target Malignant Metastatic Breast Cancer Cells Proliferating in the Marginal Sinuses.
Animals
Antibiotics, Antineoplastic
/ administration & dosage
Doxorubicin
/ administration & dosage
Drug Delivery Systems
Female
High-Energy Shock Waves
Lymph Nodes
/ drug effects
Lymphatic Metastasis
Lymphatic Vessels
/ drug effects
Mammary Neoplasms, Animal
/ drug therapy
Mice
Mice, Inbred C3H
Mice, Knockout
Sonication
/ methods
Tumor Cells, Cultured
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 09 2019
13 09 2019
Historique:
received:
01
05
2019
accepted:
23
08
2019
entrez:
15
9
2019
pubmed:
15
9
2019
medline:
31
10
2020
Statut:
epublish
Résumé
Lymph node (LN) metastasis through the lymphatic network is a major route for cancer dissemination. Tumor cells reach the marginal sinuses of LNs via afferent lymphatic vessels (LVs) and form metastatic lesions that lead to distant metastasis. Thus, targeting of metastatic cells in the marginal sinuses could improve cancer treatment outcomes. Here, we investigated whether lymphatic administration of a drug combined with sonoporation could be used to treat a LN containing proliferating murine FM3A breast cancer cells, which are highly invasive, in its marginal sinus. First, we used contrast-enhanced high-frequency ultrasound and histopathology to analyze the structure of LVs in MXH10/Mo-lpr/lpr mice, which exhibit systemic lymphadenopathy. We found that contrast agent injected into the subiliac LN flowed into the marginal sinus of the proper axillary LN (PALN) and reached the cortex. Next, we examined the anti-tumor effects of our proposed technique. We found that a strong anti-tumor effect was achieved by lymphatic administration of doxorubicin and sonoporation. Furthermore, our proposed method prevented tumor cells in the marginal sinus from invading the parenchyma of the PALN and resulted in tumor necrosis. We conclude that lymphatic administration of a drug combined with sonoporation could exert a curative effect in LNs containing metastatic cells in their marginal sinuses.
Identifiants
pubmed: 31519920
doi: 10.1038/s41598-019-49386-5
pii: 10.1038/s41598-019-49386-5
pmc: PMC6744402
doi:
Substances chimiques
Antibiotics, Antineoplastic
0
Doxorubicin
80168379AG
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13242Références
J Clin Invest. 2014 Mar;124(3):922-8
pubmed: 24590277
Sci Rep. 2016 Sep 01;6:32506
pubmed: 27581921
Cancer Res. 2013 Apr 1;73(7):2082-92
pubmed: 23333937
Biomaterials. 2010 Jul;31(19):5208-17
pubmed: 20347484
Ultrasound Med Biol. 2015 May;41(5):1411-21
pubmed: 25637527
J Control Release. 2014 Jul 28;186:22-31
pubmed: 24815422
Cancer Sci. 2017 Nov;108(11):2115-2121
pubmed: 28846190
Science. 2018 Mar 23;359(6382):1403-1407
pubmed: 29567713
Cancer Res. 2006 Dec 1;66(23):11089-93
pubmed: 17145848
Oncotarget. 2017 Apr 20;8(40):69062-69075
pubmed: 28978181
Science. 2018 Mar 23;359(6382):1408-1411
pubmed: 29567714
Asian Pac J Cancer Prev. 2016;17(S3):43-6
pubmed: 27165206
J Immunol Methods. 2015 Sep;424:100-5
pubmed: 26009246
Ultrasonics. 2015 Jan;55:1-5
pubmed: 25130135
Ultrasound Med Biol. 2015 Apr;41(4):905-28
pubmed: 25728459
Pharm Res. 2013 Jan;30(1):218-24
pubmed: 22945302
Cancer Med. 2019 May;8(5):2241-2251
pubmed: 30945479
Ultrasound Med Biol. 2014 Jun;40(6):1237-49
pubmed: 24656719
J Control Release. 2015 Jan 10;197:20-8
pubmed: 25449801
J Cancer. 2015 Oct 20;6(12):1282-94
pubmed: 26640589
Ultrasonography. 2017 Jul;36(3):171-184
pubmed: 28607323
J Electron Microsc (Tokyo). 2010;59(3):187-96
pubmed: 19906662
Cancer Sci. 2016 Mar;107(3):224-32
pubmed: 26716604
J Control Release. 2016 Jun 10;231:86-93
pubmed: 26860281
J Control Release. 2010 Jul 1;145(1):40-8
pubmed: 20398711
Pathophysiology. 2010 Sep;17(4):229-51
pubmed: 20036110
Cancer Lett. 2013 Oct 10;339(2):208-13
pubmed: 23791880
J Immunol Methods. 2013 Mar 29;389(1-2):69-78
pubmed: 23328410
Adv Drug Deliv Rev. 2014 Jun;72:49-64
pubmed: 24270006
J Exp Med. 2005 Apr 4;201(7):1089-99
pubmed: 15809353
Cancer Res. 2004 Nov 15;64(22):8239-48
pubmed: 15548690
J Control Release. 2018 Feb 28;272:169-181
pubmed: 29305924
J Control Release. 2008 Nov 12;131(3):205-10
pubmed: 18727944
Blood. 2007 Feb 1;109(3):1010-7
pubmed: 17032920
J Biophotonics. 2018 Aug;11(8):e201700401
pubmed: 29461015